Skip to main content

Table 3 Individual components of total pain burden - changes from baseline

From: Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)

 

Episodic migraine

Overall Monthly Across Months 1 to 6

Chronic migraine

Overall Monthly Across Months 1 to 3

Pain burden individual components, LS mean (SE)

Placebo

(n = 872)

Galcanezumab

(n = 435)

LS Mean Difference

(95% CI)

Placebo

(n = 535)

Galcanezumab

(n = 273)

LS Mean Difference

(95% CI)

Number of migraine headache days

−2.6 (0.2)

−4.5 (0.2)**

− 2.0 (− 2.4, − 1.6)**

− 2.7 (0.4)

−4.8 (0.4)**

− 2.1 (− 2.9, − 1.3)**

Hours per migraine headache day

0.1 (0.1)

−0.6 (0.1)**

− 0.7 (− 0.9, − 0.4)**

0.1 (0.1)

−0.5 (0.2)**

− 0.7 (− 1.0, − 0.3)**

Severity of remaining migraine headache daysa

− 0.2 (0.02)

−0.2 (0.02)*

− 0.04 (− 0.1–0.0)*

− 0.1 (0.02)

−0.2 (0.02)**

− 0.1 (− 0.1, − 0.03)**

  1. Abbreviations: CI confidence interval, LS least squares, SE standard error
  2. *p < 0.05 versus placebo
  3. **p ≤ 0.001 versus placebo
  4. aSeverity measured as: none = 0, mild = 1, moderate = 2, severe = 3